Business Wire

MBZIRC

28.9.2021 13:46:05 CEST | Business Wire | Press release

Share
Abu Dhabi’s ASPIRE Launches Over US$3 Million MBZIRC Maritime Grand Challenge

The Mohamed Bin Zayed International Robotics Challenge (MBZIRC) will be held in the UAE capital, Abu Dhabi, in June 2023, where tech innovators will participate to seek marine safety and security solutions to take home more than US$3 million in prize money.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005641/en/

Organised by ASPIRE, the dedicated technology programme management pillar of the Advanced Technology Research Council (ATRC), the overarching advanced technology research body in Abu Dhabi, UAE, the MBZIRC is held every two years. The upcoming edition, called MBZIRC Maritime Grand Challenge, focuses on real-time solutions to maritime safety and security challenges and seeks to claim its place among the largest and most prestigious AI and robotics competitions in the world.

The Challenge is open to international universities, research institutions, companies and individual innovators from all over the world. It will involve a heterogeneous collaboration among unmanned aerial vehicles and unmanned surface vehicles, to perform complex navigation and manipulation tasks in a GNSS-denied environment. Call for registrations is now open.

Commenting on the announcement, H.E. Faisal Al Bannai , Secretary General of ATRC, said: “We are proud that MBZIRC is going global by inviting the best talent from all over the world to participate. We have set a tough real-world challenge that will push the participants to the limits of their capabilities. The event is a great opportunity to demonstrate the pioneering scientific research work that is taking place in Abu Dhabi and the UAE.”

The challenge will show how both entities focus on niche areas of technology, while attracting global innovators to stimulate ideas, encourage collaboration, and push boundaries in advanced technologies to find systems solutions to global challenges.

“For countries with long coastlines, ensuring maritime safety requires significant investment in sophisticated equipment and highly trained personnel. Using advanced robotic systems can not only help reduce costs, but also handle some of the often- dangerous tasks performed by humans. The motivation for holding the MBZIRC Maritime Grand Challenge is to take the technology out of the laboratory and test it in a real-world environment to see what is possible,” said Dr Arthur Morrish, Chief Executive of ASPIRE.

Dr Morrish underscored the two-fold purpose behind the competition: one is to focus on the important problems in autonomy of robotics while engaging the world community in a hard robotics challenge. The other is to find a solution to a real-world challenge facing the world.

The challenge is for a swarm of UAVs to identify a target vessel from several similar vessels in open waters in a GNSS-denied environment, and to offload specific items from the target onto an USV in the shortest possible time using autonomous technologies. This is a new kind of kind of exercise in autonomous robotics. “A nice thing about this challenge is that you tell people what you want, but you don’t specify an approach to do it,” Dr Morrish added.

He said that this kind of a smart system will have practical application in other areas as well, especially as it can perform complex tasks of autonomous intervention in a GNSS-denied environment.

For more information, visit www.mbzirc.com

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye